Talis Biomedical to Participate in Upcoming BofA Securities 2021 Virtual Healthcare Conference
Talis Biomedical Corporation (TLIS) announced its participation in the BofA Securities 2021 Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talis Biomedical Corporation (TLIS) announced its participation in the BofA Securities 2021 Virtual Healthcare Conference. The company's management will present on May 12, 2021, at 8:00 a.m. PT / 11:00 a.m. ET. Interested investors can watch the live and archived webcast on Talis's website. Talis Biomedical is focused on developing innovative molecular diagnostic tests for infectious diseases, featuring its compact, cloud-enabled diagnostic platform, Talis One.
Details
News Market Reaction – TLIS
The recorded move for TLIS in the trading session of this news was +0.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (“TLIS”), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that the company will be participating in the BofA Securities 2021 Virtual Healthcare Conference.
Talis Biomedical’s management is scheduled to participate in the conference on Wednesday, May 12, 2021, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Interested parties can access the live and archived webcast via the News & Events page of the investor section of the company’s website at www.talis.bio.
About Talis Biomedical
Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost, and rapid molecular testing for infectious diseases at the point-of-care. The company is developing the Tails One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. For more information, visit www.talis.bio.
Investor Contact
Media & Investors
Emily Faucette
efaucette@talisbio.com
415-595-9407
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.